Diagnostics: Page 46


  • Image attribution tooltip
    "Florida National Guard" by The National Guard is licensed under CC BY 2.0
    Image attribution tooltip

    5-minute, quantitative COVID-19 antibody test snags BARDA backing

    MBio's offering could assess whether a patient has protective levels of antibodies and is a candidate to donate convalescent plasma, a potential treatment for critically ill COVID-19 patients.

    By June 24, 2020
  • CVS launches COVID-19 return-to-work service with testing

    Questions about testing accuracy and hesitancy by employers haven't stopped big healthcare companies, including Quest, LabCorp and UnitedHealth Group, from jumping into the space with new products.

    By Rebecca Pifer Parduhn • June 24, 2020
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • A piece of DNA stretches vertically along a plain background.
    Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    New Guardant genomic database could be worth $2B, analysts say

    The company said clinical information from repeat liquid biopsies in its 86,000-patient database will show how tumors evolve, information that may be attractive to biopharma partners.

    By June 24, 2020
  • Members of the Army and Air National Guard from across several states have been activated under Operation COVID-19 to support federal, state and local efforts. (
    Image attribution tooltip
    The image by The National Guard is licensed under CC BY 2.0
    Image attribution tooltip
    Deep Dive

    No silver bullet: LabCorp and Quest hawk return-to-work COVID-19 tests but employers not rushing in

    One employer group official noted "hype" around antibody testing with inconclusive evidence about the immunity of individuals who test positive for the antibodies. 

    By June 22, 2020
  • BARDA backs study of Empatica's COVID-19 early warning platform

    The system, which measures physiological data including blood volume pulse and electrodermal activity, is the latest in a growing list of wearables being primed to detect and monitor infections.

    By June 22, 2020
  • Trump admin sitting on $14B for testing, tracing, Democratic senators say

    A letter urging the administration to ramp up its COVID-19 spending comes a day after President Donald Trump told a rally he had directed officials to slow down testing to keep case numbers low.

    By Rebecca Pifer Parduhn • June 22, 2020
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    Invitae cash-and-stock buyout of ArcherDX a done deal

    The medical genetic testing company swept in after the assay developer announced plans to go public. Invitae will now offer tests for more stages of cancer care, from assessing disease risk to monitoring its progression.

    By Maria Rachal • Updated Oct. 5, 2020
  • President Trump listens as FDA Commissioner Stephen Hahn delivers remarks at COVID-19 update briefing on April 24, 2020
    Image attribution tooltip
    Dufour, Tia. (2020). "White House Press Briefing" [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says

    The agency has grappled with how to leverage real-world data in regulating medical devices, and is now leaning on it to update emergency use authorizations, FDA chief Stephen Hahn said at a forum on Thursday.

    By Maria Rachal • June 19, 2020
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/MedTech Dive
    Image attribution tooltip

    FDA cracks down on sellers of at-home COVID-19 antibody tests

    A series of warning letters is the latest example of U.S. regulators weeding out serology tests that don't meet the agency's standards.

    By June 18, 2020
  • TÜV SÜD becomes 4th notified body designated under IVDR

    It's the first notified body OK'd by the European Commission in 2020 to increase capacity for the forthcoming In Vitro Diagnostic Regulation, set to come into force in less than two years.

    By June 18, 2020
  • FDA revokes emergency authorization for Chembio's COVID-19 antibody test

    It's the first time the agency has exercised such authority for a coronavirus test, citing more false results than expected. Chembio Diagnostics' stock plunged 60% Wednesday.

    By June 17, 2020
  • NIH loops Quest into effort to test 10K Americans for antibodies against coronavirus

    The agency did not disclose which antibody test it will use as part of the All of Us initiative, saying only that the assay has FDA emergency use authorization and is designed to detect IgG antibodies. 

    By June 17, 2020
  • Myriad prostate cancer test wins coverage from Aetna

    The decisions by the insurance giant and two others nearly double commercial coverage for the Prolaris test, days after a local Medicare contractor found there may be insufficient data to back Myriad's GeneSight combinatorial tests.

    By June 16, 2020
  • Labs urge CDC to change COVID-19 antibody test guidelines

    The trade group for Quest Diagnostics and LabCorp criticized the federal agency's advice against use of serology test results to make decisions about who can return to work.

    By June 16, 2020
  • New Jersey Air National Guard medics with the 108th Wing process specimens at a COVID-19 Community-Based Testing Site at the PNC Bank Arts Center in Holmdel, N.J., March 23, 2020. The testing site, es
    Image attribution tooltip
    Master Sgt. Hecht, Matt. (2020). [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    COVID-19 diagnostic testing costs may hit $25B per year, AHIP study finds

    And on the antibody testing front, costs could range between $5.2 billion and $19.1 billion, according to a report commissioned by the payer trade group.

    By Shannon Muchmore • June 11, 2020
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Cue Health raises $100M to scale up rapid, portable coronavirus test

    The startup, which counts J&J among its backers, said on Friday it received FDA emergency use authorization for its test, allowing use anywhere under the supervision of qualified medical personnel. 

    By Updated June 12, 2020
  • MedTech Europe pitches virtual audits to clear MDR coronavirus logjam

    The trade group contends technology such as smart glasses and webcams can enable notified bodies to view facilities without having to visit in person.

    By June 11, 2020
  • Image attribution tooltip
    "200323-Z-IB607-0016" by New Jersey National Guard is licensed under CC BY-ND 2.0
    Image attribution tooltip

    Cepheid developing test to distinguish COVID-19 from flu

    The company, which plans to pursue the FDA's emergency use authorization pathway for the four-in-one combination test, is aiming to have it ready for next flu season, when a potential spike in coronavirus cases could occur.

    By June 10, 2020
  • DOJ charges medtech exec with $69M in COVID-19 test fraud, notes Theranos parallel

    The Department of Justice said the case against an Arrayit Corporation exec is the first criminal securities fraud prosecution in relation to the pandemic.

    By June 10, 2020
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/MedTech Dive
    Image attribution tooltip

    Ex-FDA chief scientist slams 'chaos' caused by agency approach to antibody tests

    Jesse Goodman said the agency’s decision to allow developers of COVID-19 serology tests to self-validate their products led unqualified entities to flood the market.

    By June 10, 2020
  • Geisinger's campus
    Image attribution tooltip
    Permission granted by Geisinger Health
    Image attribution tooltip

    Siemens Healthineers, Geisinger ink 10-year digital health partnership

    It's one of the medtech's largest partnerships of its kind in North America, as it plans to provide diagnostic imaging and artificial intelligence-enabled applications to the health system over the next decade.

    By June 9, 2020
  • covid-19 coronavirus microscopic image with blue colored viral particles
    Image attribution tooltip
    CDC/Hannah A Bullock; Azaibi Tamin. (2019). "covid-19 coronavirus microscopic image with blue colored viral particles". Retrieved from https://www.cdc.gov/media/subtopic/images.htm.
    Image attribution tooltip

    FDA expands at-home, saliva-based coronavirus testing with nod to Phosphorus

    Individuals can obtain a test kit from the genomics startup without using an outside telemedicine platform.

    By June 9, 2020
  • Image attribution tooltip
    Peter Ashkenaz, ONC
    Image attribution tooltip

    Lawmakers push HHS to funnel funds to clinical labs amid routine testing decline

    Members of Congress on both sides of the aisle argue the investments laboratories are making to scale up COVID-19 testing mean they need more targeted financial support, which should come out of a $25 billion relief fund.

    By June 9, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    COVID-19 false negatives fuel call for urgent focus on asymptomatic patients

    Harvard and Yale physicians writing in the New England Journal of Medicine called for development of a reference standard for measuring sensitivity of coronavirus tests in those without symptoms who may infect others.

    By June 8, 2020
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    Healthcare sector adds 312K jobs in May, but hospitals left out

    A collective uptick of roughly 124,000 jobs in health professional and physician offices suggests patients who have been delaying non-urgent medical care are back and seeking treatment outside hospitals. 

    By Hailey Mensik • Updated June 8, 2020